Gaithersburg vaccine developer raises $21 million

Gaithersburg vaccine developer VLP Therapeutics Inc. has raised $21 million in a Series A-1 funding round, its second round this year, the company said in a press release Monday. The latest round will be used to accelerate research and development of a cancer treatment vaccine, the company said, in addition to preventative malaria and dengue vaccines. "We were fortunate enough to be able to raise funding in March to facilitate our cancer treatment vaccine R&D, ” Wataru Akahata, VLP's co-founder,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news